An update from Rakovina Therapeutics Inc ( (TSE:RKV)) is now available. At the 9th Annual DDR Inhibitors Summit, Rakovina reported strong industry validation for its brain-penetrant dual ATR/mTOR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results